[A26-29] Donanemab (early Alzheimer’s disease) – Addendum to Project A25-134
Last updated 16.04.2026
Project no.:
A26-29
Commission:
Commission awarded on 10.03.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults with early Alzheimer’s disease with confirmed amyloid pathology who are ApoE ε4 non-carriers or heterozygotes
Result of dossier assessment:
- Patients with clinically diagnosed mild cognitive impairment (MCI) due to Alzheimer’s disease: unchanged after addendum: added benefit not proven
- Patients with clinically diagnosed mild dementia due to Alzheimer’s disease: unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
DOI:
https://doi.org/10.60584/A26-29
| Project no. | Title | Status |
|---|---|---|
| A25-134 | Donanemab (early Alzheimer’s disease) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
16-04-2026 A G-BA decision was published.
G-BA documents on this decision